During the two-day meeting, the eight project partner organisations will present the latest progress achieved across the different Work Packages and discuss next steps in advancing the ALADDIN platform for accelerated nanobody discovery.

The event will also provide an opportunity to strengthen collaboration within the consortium, exchange ideas, and explore directions for research and innovation.

The Annual Meeting represents another important milestone in ALADDIN’s mission to accelerate the development and validation of next-generation nanobody-based treatments for cancer.

Stay tuned for updates on the ALADDIN social media channels during the meeting: LinkedIn, Bluesky and X.